文献速递消化道肿瘤与早癌消化内镜

低危与高危T1b食管腺癌内镜治疗后的临床结局:国际研究患者水平汇总分析

Clinical Outcomes After Endoscopic Management of Low-Risk and High-Risk T1b Esophageal Adenocarcinoma: A Patient-Level Pooled Analysis of International Studies.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-06-11

该研究汇总7项研究216例内镜切除后深切缘阴性的T1b食管腺癌患者,比较低危与高危(黏膜下2/3或>500μm浸润、脉管侵犯或低分化)的长期结局。

要点

  • 低危T1b食管腺癌内镜治疗后腔外转移和癌因死亡极低,支持内镜根治治疗。
  • 高危T1b(深浸润、脉管侵犯或低分化)腔外转移风险约5倍于低危组。
  • 高危T1b需谨慎选择患者并共享决策,权衡内镜与手术。

核心结论

  • 低危T1b食管腺癌内镜治疗后腔外转移和癌因死亡极低,支持内镜根治治疗。
  • 高危T1b食管腺癌结局显著更差,需谨慎选择患者并共享决策。

研究设计与样本

  • 国际多研究个体患者水平数据汇总分析,纳入内镜切除深切缘阴性的T1b食管腺癌。
  • 共纳入7项研究216例患者,84%男性,94%白人,中位随访48.1个月(IQR 25.5-68.1)。
  • 高危定义:黏膜下2/3或深>500μm浸润、脉管侵犯或低分化;高危组114例(53%)。

关键数值与推荐

  • 高危T1b定义:黏膜下2/3或深>500μm浸润、脉管侵犯或低分化。

临床怎么用

  • 低危T1b食管腺癌可考虑内镜根治治疗。
  • 高危T1b应充分评估腔外转移风险,谨慎选择内镜治疗并共享决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endoscopic eradication therapy is standard of care for T1a esophageal adenocarcinoma. There are limited data regarding long-term outcomes of endoscopic eradication therapy for T1b esophageal adenocarcinoma. The aim of this study was to assess clinical outcomes after endoscopic management of low-risk and high-risk T1b esophageal adenocarcinoma via a pooled analysis of individual patient-level data. METHODS: A pooled analysis of studies reporting endoscopic management of T1b esophageal adenocarcinoma was conducted. Inclusion required endoscopic resection revealing T1b esophageal adenocarcinoma with negative deep margins. High-risk T1b esophageal adenocarcinoma was defined by presence of: submucosal 2/3 or deep (>500 μm) submucosal invasion, lymphovascular invasion, or poor grade of differentiation. Clinical outcomes included all-cause and esophageal adenocarcinoma-related mortality, intraluminal recurrence, and extraluminal metastases. RESULTS: Of 418 studies identified, 7 with 216 patients were included (84% men; 94% White). The median follow-up was 48.1 months (interquartile range, 25.5-68.1 months). High-risk T1b esophageal adenocarcinoma was observed in 114 patients (53%). Baseline clinical characteristics were mostly similar between groups. Although the rates of intraluminal recurrence in the low-risk and high-risk groups were comparable (15% vs 22%; P = .30), the high-risk group had a 5-fold significantly higher risk of extraluminal metastases (11% vs 2%; P = .01). Both all-cause and esophageal adenocarcinoma-related mortality were significantly higher in the high-risk group (log rank P = .04). CONCLUSIONS: In this international pooled analysis, rates of extraluminal metastases and esophageal adenocarcinoma-related mortality were very low in patients with low-risk T1b esophageal adenocarcinoma, supporting the role of endoscopic eradication therapy in this group. However, outcomes were significantly worse for the high-risk T1b group, suggesting careful patient selection and shared decision-making in this population.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kamboj AK, Dilmaghani S, Goyal R, et al. Clinical Outcomes After Endoscopic Management of Low-Risk and High-Risk T1b Esophageal Adenocarcinoma: A Patient-Level Pooled Analysis of International Studies. Clin Gastroenterol Hepatol. 2026. PMID: 42276313. doi:10.1016/j.cgh.2026.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。